Alternative treatments have developed to counter these pitfalls, and one of them is the introduction of intravitreal injections of anti-VEGF agents like bevacizumab and ranibizumab, which directly inhibit VEGF and seem to reduce macular edema with encouraging results in visual acuity improvement. The gene discussed is VEGFA; the disease is macular retinal edema.